A diclofenac suppository–nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis. (24th January 2013)
- Record Type:
- Journal Article
- Title:
- A diclofenac suppository–nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis. (24th January 2013)
- Main Title:
- A diclofenac suppository–nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis
- Authors:
- Setoguchi, Nao
Takamura, Norito
Fujita, Ken‐ichi
Ogata, Kenji
Tokunaga, Jin
Nishio, Toyotaka
Chosa, Etsuo
Arimori, Kazuhiko
Kawai, Keiichi
Yamamoto, Ryuichi - Abstract:
- <abstract abstract-type="main"> <title>ABSTRACT</title> <p>Diclofenac suppository, a non‐steroidal anti‐inflammatory drug (NSAID), is used widely in rheumatoid arthritis (RA) patients with severe arthritic pain. As the binding percentage of diclofenac to serum proteins is high, its free (unbound) concentration after rectal administration is low. To increase temporarily the free concentration of diclofenac and to enhance its analgesic effect by inhibiting the protein binding of diclofenac, the analgesic effect of diclofenac was examined before and after the start of an inhibitor administration to RA patients with insufficient control of arthritic pain, and the protein binding capacity of diclofenac was evaluated. Binding experiments were performed by ultrafiltration, and arthritic pain was recorded by the face scale. Free fractions of diazepam and diclofenac were augmented by increasing 6‐methoxy‐2‐naphthylacetic acid (6‐MNA; the active metabolite of the NSAID nabumetone) concentrations. The free fraction of diazepam increased after the start of nabumetone administration to RA patients, and arthritic pain relief was observed. These results suggest that 6‐MNA has an inhibitory effect on the protein binding of diclofenac and the free fraction of diazepam can be used to evaluate the binding capacity of diclofenac. It is considered that diclofenac suppository–nabumetone combination therapy and the method for protein binding monitoring by diazepam can positively benefit RA<abstract abstract-type="main"> <title>ABSTRACT</title> <p>Diclofenac suppository, a non‐steroidal anti‐inflammatory drug (NSAID), is used widely in rheumatoid arthritis (RA) patients with severe arthritic pain. As the binding percentage of diclofenac to serum proteins is high, its free (unbound) concentration after rectal administration is low. To increase temporarily the free concentration of diclofenac and to enhance its analgesic effect by inhibiting the protein binding of diclofenac, the analgesic effect of diclofenac was examined before and after the start of an inhibitor administration to RA patients with insufficient control of arthritic pain, and the protein binding capacity of diclofenac was evaluated. Binding experiments were performed by ultrafiltration, and arthritic pain was recorded by the face scale. Free fractions of diazepam and diclofenac were augmented by increasing 6‐methoxy‐2‐naphthylacetic acid (6‐MNA; the active metabolite of the NSAID nabumetone) concentrations. The free fraction of diazepam increased after the start of nabumetone administration to RA patients, and arthritic pain relief was observed. These results suggest that 6‐MNA has an inhibitory effect on the protein binding of diclofenac and the free fraction of diazepam can be used to evaluate the binding capacity of diclofenac. It is considered that diclofenac suppository–nabumetone combination therapy and the method for protein binding monitoring by diazepam can positively benefit RA patients with insufficient control of arthritic pain. Copyright © 2013 John Wiley &amp; Sons, Ltd.</p> </abstract> … (more)
- Is Part Of:
- Biopharmaceutics & drug disposition. Volume 34:Number 2(2013:Mar.)
- Journal:
- Biopharmaceutics & drug disposition
- Issue:
- Volume 34:Number 2(2013:Mar.)
- Issue Display:
- Volume 34, Issue 2 (2013)
- Year:
- 2013
- Volume:
- 34
- Issue:
- 2
- Issue Sort Value:
- 2013-0034-0002-0000
- Page Start:
- 125
- Page End:
- 136
- Publication Date:
- 2013-01-24
- Subjects:
- Biopharmaceutics -- Periodicals
Drugs -- Metabolism -- Periodicals
Pharmacology -- Periodicals
Biopharmaceutics -- Periodicals
Pharmaceutical Preparations -- metabolism -- Periodicals
615.19 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/bdd.1829 ↗
- Languages:
- English
- ISSNs:
- 0142-2782
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2089.355000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3836.xml